Fig. 3. Osimertinib-induced expression of CXCL10 and IL6 is NFkB and JAK/STAT pathway dependent.

a PC9, H1650, H1975, and HCC827 cells were treated with DMSO or 300 nM osimertinib alone and in combination with 500 nM IKK16 or 500 nM ruxolitinib. All cell lines were treated for 7 days except PC9 cells which were treated for 3 days. Secreted CXCL10 and IL6 were measured by ELISA. The data are from three independent experiments and were submitted to one-way ANOVA and statistical significance of the osimertinib-treated samples relative to their DMSO controls is shown. b PC9 cells expressing the dnIκB protein or empty vector as a control were treated with 300 nM osimertinib or DMSO control for 3 days and CXCL10 and IL6 protein secretion into the media was measured by ELISA. The data are the mean and SEM of three independent experiments and presented as pg/μg protein.